Expression of the interleukin-2 receptor (Tac antigen/CD25) in hematologic neoplasms

W. N. Erber, D. Y. Mason

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The expression of interleukin-2 (IL-2) receptor (CD25) has been investigated in 165 cases of hematologic neoplasia by alkaline phosphatase-antialkaline phosphatase (APAAP) labeling of cell smears using two monoclonal anti-IL-2 receptor antibodies (anti-Tac and DAKO-IL2-R). IL-2 receptor was found in 2 of 16 (13%) T-cell malignancies (1 T-ALL, 1 Sezary syndrome). In contrast, among B-cell disorders, IL-2 receptor was expressed in the majority of hairy cell leukemia cases (14 of 16, i.e., 88%) and in a smaller proportion of cases of common acute lymphoblastic leukemia (7 of 44, i.e., 16%), B-cell chronic lymphocytic leukemia (8 of 20, i.e., 40%), B-cell prolymphocytic leukemia (3 of 5), and B-cell lymphoma (3 of 8). In addition, IL-2 receptor was present on the neoplastic cells in some cases of acute myeloid leukemia (6 of 44, i.e., 14%) and acute undifferentiated leukemia (4 of 7). IL-2 receptor (Tac antigen) expression is thus found across the spectrum of hematologic neoplasms and is not restricted to T-cell disorders. The explanation for the expression of the IL-2 receptor by such a variety of different hematologic malignancies remains unclear.

Original languageEnglish
Pages (from-to)645-648
Number of pages4
JournalAmerican Journal of Clinical Pathology
Volume89
Issue number5
DOIs
Publication statusPublished - 1 Jan 1988
Externally publishedYes

Fingerprint

Interleukin-2 Receptor alpha Subunit
Interleukin-2 Receptors
Hematologic Neoplasms
B-Cell Prolymphocytic Leukemia
Sezary Syndrome
T-Lymphocytes
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Hairy Cell Leukemia
B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phosphoric Monoester Hydrolases
Acute Myeloid Leukemia
Interleukin-2
Alkaline Phosphatase
Anti-Idiotypic Antibodies
Neoplasms
Leukemia
B-Lymphocytes
Antigens

Cite this

@article{d3428a45c650438f9f971ee473585b86,
title = "Expression of the interleukin-2 receptor (Tac antigen/CD25) in hematologic neoplasms",
abstract = "The expression of interleukin-2 (IL-2) receptor (CD25) has been investigated in 165 cases of hematologic neoplasia by alkaline phosphatase-antialkaline phosphatase (APAAP) labeling of cell smears using two monoclonal anti-IL-2 receptor antibodies (anti-Tac and DAKO-IL2-R). IL-2 receptor was found in 2 of 16 (13{\%}) T-cell malignancies (1 T-ALL, 1 Sezary syndrome). In contrast, among B-cell disorders, IL-2 receptor was expressed in the majority of hairy cell leukemia cases (14 of 16, i.e., 88{\%}) and in a smaller proportion of cases of common acute lymphoblastic leukemia (7 of 44, i.e., 16{\%}), B-cell chronic lymphocytic leukemia (8 of 20, i.e., 40{\%}), B-cell prolymphocytic leukemia (3 of 5), and B-cell lymphoma (3 of 8). In addition, IL-2 receptor was present on the neoplastic cells in some cases of acute myeloid leukemia (6 of 44, i.e., 14{\%}) and acute undifferentiated leukemia (4 of 7). IL-2 receptor (Tac antigen) expression is thus found across the spectrum of hematologic neoplasms and is not restricted to T-cell disorders. The explanation for the expression of the IL-2 receptor by such a variety of different hematologic malignancies remains unclear.",
author = "Erber, {W. N.} and Mason, {D. Y.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1093/ajcp/89.5.645",
language = "English",
volume = "89",
pages = "645--648",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

Expression of the interleukin-2 receptor (Tac antigen/CD25) in hematologic neoplasms. / Erber, W. N.; Mason, D. Y.

In: American Journal of Clinical Pathology, Vol. 89, No. 5, 01.01.1988, p. 645-648.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of the interleukin-2 receptor (Tac antigen/CD25) in hematologic neoplasms

AU - Erber, W. N.

AU - Mason, D. Y.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The expression of interleukin-2 (IL-2) receptor (CD25) has been investigated in 165 cases of hematologic neoplasia by alkaline phosphatase-antialkaline phosphatase (APAAP) labeling of cell smears using two monoclonal anti-IL-2 receptor antibodies (anti-Tac and DAKO-IL2-R). IL-2 receptor was found in 2 of 16 (13%) T-cell malignancies (1 T-ALL, 1 Sezary syndrome). In contrast, among B-cell disorders, IL-2 receptor was expressed in the majority of hairy cell leukemia cases (14 of 16, i.e., 88%) and in a smaller proportion of cases of common acute lymphoblastic leukemia (7 of 44, i.e., 16%), B-cell chronic lymphocytic leukemia (8 of 20, i.e., 40%), B-cell prolymphocytic leukemia (3 of 5), and B-cell lymphoma (3 of 8). In addition, IL-2 receptor was present on the neoplastic cells in some cases of acute myeloid leukemia (6 of 44, i.e., 14%) and acute undifferentiated leukemia (4 of 7). IL-2 receptor (Tac antigen) expression is thus found across the spectrum of hematologic neoplasms and is not restricted to T-cell disorders. The explanation for the expression of the IL-2 receptor by such a variety of different hematologic malignancies remains unclear.

AB - The expression of interleukin-2 (IL-2) receptor (CD25) has been investigated in 165 cases of hematologic neoplasia by alkaline phosphatase-antialkaline phosphatase (APAAP) labeling of cell smears using two monoclonal anti-IL-2 receptor antibodies (anti-Tac and DAKO-IL2-R). IL-2 receptor was found in 2 of 16 (13%) T-cell malignancies (1 T-ALL, 1 Sezary syndrome). In contrast, among B-cell disorders, IL-2 receptor was expressed in the majority of hairy cell leukemia cases (14 of 16, i.e., 88%) and in a smaller proportion of cases of common acute lymphoblastic leukemia (7 of 44, i.e., 16%), B-cell chronic lymphocytic leukemia (8 of 20, i.e., 40%), B-cell prolymphocytic leukemia (3 of 5), and B-cell lymphoma (3 of 8). In addition, IL-2 receptor was present on the neoplastic cells in some cases of acute myeloid leukemia (6 of 44, i.e., 14%) and acute undifferentiated leukemia (4 of 7). IL-2 receptor (Tac antigen) expression is thus found across the spectrum of hematologic neoplasms and is not restricted to T-cell disorders. The explanation for the expression of the IL-2 receptor by such a variety of different hematologic malignancies remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=0023880985&partnerID=8YFLogxK

U2 - 10.1093/ajcp/89.5.645

DO - 10.1093/ajcp/89.5.645

M3 - Article

VL - 89

SP - 645

EP - 648

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -